Sandoz receives EC approval for biosimilar therapy Pyzchiva® (ustekinumab) from Samsung Bioepis.
Sandoz confirms European Commission's approval of Pyzchiva® (ustekinumab), a biosimilar therapy for gastroenterology, dermatology, and rheumatology. The approval follows a deal with Samsung Bioepis, where Sandoz has exclusive commercialization rights in certain regions. This move strengthens Sandoz's immunology portfolio and aims to accelerate access to potentially life-changing treatments.
April 22, 2024
5 Articles